Related Experiment Video
Updated: Aug 12, 2026
Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
Therapeutic efficacy of E2F1 in pancreatic cancer correlates with TP73 induction
F Rödicker1, T Stiewe, S Zimmermann
1Centre for Cancer Research and Cancer Therapy, Institute of Molecular Biology, University of Essen, Medical School, D-45122 Essen, Germany.
Abstract:
Pancreatic cancer is particularly resistant to apoptosis by antineoplastic agents, which is partly attributable to the lack of functional p53. Here we show that E2F1 in combination with the most clinically efficient drug, gemcitabine, resulted in a strong induction of apoptosis independent of functional p53, whereas the effect of either therapy alone varied between different cell lines. Intratumoral injection of a helper-dependent adenovirus vector expressing E2F1 plus drug treatment resulted in a significant reduction of tumor volume. The therapeutic effect is directly correlated with the induction of the p53 homologue p73, suggesting that the recently discovered E2F1/p73 pathway plays a critical role in cancer therapy.
Insights
Pancreatic cancers resistant to chemotherapy can be treated by combining E2F1 gene therapy with gemcitabine. This approach induces apoptosis independently of p53, offering a new strategy for pancreatic cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Pancreatic cancer exhibits resistance to apoptosis induced by antineoplastic agents.
- This resistance is often linked to a lack of functional p53 tumor suppressor protein.
Purpose of the Study:
- To investigate the efficacy of combining E2F1 gene therapy with gemcitabine in overcoming chemoresistance in pancreatic cancer.
- To explore the role of the E2F1/p73 pathway in mediating apoptosis and therapeutic response.
Main Methods:
- Utilized a helper-dependent adenovirus vector to deliver E2F1.
- Administered gemcitabine, a clinically efficient chemotherapeutic agent.
- Evaluated apoptosis induction and tumor volume reduction in preclinical models.
Main Results:
- Combination therapy (E2F1 plus gemcitabine) strongly induced apoptosis, independent of functional p53.
- Single-agent therapies showed variable effects across different cell lines.
- Intratumoral E2F1 delivery combined with gemcitabine significantly reduced tumor volume.
- Therapeutic efficacy correlated with the induction of p73, a p53 homologue.
Conclusions:
- The E2F1/p73 pathway is critical for mediating apoptosis and enhancing the therapeutic effect of gemcitabine in pancreatic cancer.
- This combination strategy offers a promising approach for treating chemoresistant pancreatic tumors.
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:23Abnormal Proliferation